



Attorney Docket No.: 3800073.00005 / 922

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gantier *et al.*
Patent No. : 7,611,700
Issue Date : November 3, 2009
Serial No. : 10/658,834
Filed : September 8, 2003

Art Unit : 1647
Examiner : Stoica, Elly Gerald
Conf. No. : 7681
Cust. No. : 77202

Title : **PROTEASE RESISTANT MODIFIED INTERFERON ALPHA
POLYPEPTIDES**

Attn: Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are a Request for Correction to Certificate of Correction (2 pages), Certificate of Correction (1 page), a hand-corrected version of the issued Certificate of Correction issued on March 4, 2010 (2 pages), and a return postcard for filing in connection with the above-identified application. All errors sought to be corrected were made in printing by the Patent and Trademark Office, and no fee is believed to be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 02-1818, as stated below:

☒ The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 02-1818. A duplicate of this sheet is enclosed.


Respectfully submitted,


Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 3800073.00005/ 922
Address all correspondence to: 77202
Stephanie Seidman
K&L Gates LLP
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130
Telephone: (858) 509-7410
Facsimile: (858) 509-7460
email: stephanie.seidman@klgates.com

Certificate
JUN 18 2010
of Correction

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number: EM 315456523 US
Date of Deposit: June 14, 2010
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Attn: Certificate of Correction Branch, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.


Jonathan Witt



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gantier *et al.*

Art Unit : 1647

Patent No. : 7,611,700

Examiner : Stoica, Elly Gerald

Issue Date : November 3, 2009

Conf. No. : 7681

Serial No. : 10/658,834

Cust. No. : 77202

Filed : September 8, 2003

Title : **PROTEASE RESISTANT MODIFIED INTERFERON ALPHA
POLYPEPTIDES**

Attn: Certificate of Corrections Branch

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are a Request for Correction to Certificate of Correction (2 pages), Certificate of Correction (1 page), a hand-corrected version of the issued Certificate of Correction issued on March 4, 2010 (2 pages), and a return postcard for filing in connection with the above-identified application. All errors sought to be corrected were made in printing by the Patent and Trademark Office, and no fee is believed to be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 02-1818, as stated below:

☒ The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 02-1818. A duplicate of this sheet is enclosed.

Respectfully submitted,


Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 3800073.00005/ 922

Address all correspondence to: 77202

Stephanie Seidman

K&L Gates LLP

3580 Carmel Mountain Road, Suite 200

San Diego, California 92130

Telephone: (858) 509-7410

Facsimile: (858) 509-7460


email: stephanie.seidman@klgates.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number: EM 315456523 US

Date of Deposit: June 14, 2010

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Attn: Certificate of Correction Branch, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.


Jonathan Witt



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gantier *et al.*
Patent No. : 7,611,700
Issue Date : November 3, 2009
Serial No. : 10/658,834
Filed : September 8, 2003
Title : **PROTEASE RESISTANT MODIFIED INTERFERON ALPHA
POLYPEPTIDES**

Art Unit : 1647
Examiner : Stoica, Elly Gerald
Conf. No. : 7681
Cust. No. : 77202

Attn.: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTION TO ISSUED CERTIFICATE OF CORRECTION

Dear Sir:

Issuance of a corrected Certificate of Correction for the above-referenced patent respectfully is requested. A new error was introduced by the PTO in the Certificate of Correction issued on May 4, 2010. Correction of the following error introduced by the PTO respectfully is requested:

In issued Claim 1, on page 2 of the Certificate of Correction issued on May 4, 2010, in line 21 the PTO incorrectly printed "á-2c" in place of "α-2c". Please replace "á-2c" so that the claim now recites — α-2c —, as originally recited in the issued patent.

A hand-corrected version of the Certificate of Correction issued on May 4, 2010 for the above captioned patent is attached. Also attached is a new Certificate of Correction, which correctly presents Claim 1.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number: EM 315456523 US
Date of Deposit: June 14, 2010.

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Attn.: Certificate of Correction Branch Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.


Jonathan Witt

Applicant : Gantier *et al.*
Patent No. : 7,611,700
Issue Date : November 3, 2009
Serial No. : 10/658,834
Filed : September 8, 2003

Attorney Docket No.: 3800073.00005 / 922
Request for Correction to Issued Certificate of Correction

The error sought to be corrected was made in printing by the Patent and Trademark Office, and no fee should be due. If it is determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 02-1818.

Respectfully submitted,



Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 3800073.00005 / 922
Address all correspondence to: 77202
Stephanie Seidman
K&L Gates LLP
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130
Telephone: (858) 509-7410
Facsimile: (858) 509-7460
email: stephanie.seidman@klgates.com

Applicant : Gantier *et al.*
Patent No. : 7,611,700
Issue Date : November 3, 2009
Serial No. : 10/658,834
Filed : September 8, 2003

Attorney's Docket No.: 3800073.00005 / 922
Request for Correction to Issued Certificate of Correction

NEW CERTIFICATE OF CORRECTION
PROVIDING CLAIM 1

Staple
Here
Only**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**Page 1 of 1

PATENT NO. .: 7,611,700
APPLICATION NO .: 10/658,834
DATED .: NOVEMBER 3, 2009
INVENTOR(S) .: GANTIER ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE CLAIMS:

Column 87, line 32 to Column 87, line 47

1. An isolated interferon (IFN) alpha cytokine, comprising an amino acid replacement in its sequence of amino acids, wherein:
an amino acid replacement is E41Q, whereby the interferon alpha cytokine exhibits increased resistance to proteolysis so that it can be administered orally compared to the unmodified interferon alpha cytokine that does not comprise the amino acid replacement; and
in the interferon-alpha cytokine the interferon is not glycosylated at E41Q; and
the unmodified interferon alpha cytokine is selected from among an interferon α -2b (IFN α -2b), an interferon α -2a (IFN α -2a), an interferon α -2c (IFN α -2c) and consensus interferon whose sequences are set forth in SEQ ID Nos. 1, 182, 185 and 232, respectively.

MAILING ADDRESS OF SENDER:

Stephanie Seidman
K&L Gates, LLP
3580 Carmel Mountain Road, Suite 200
San Diego, CA, 92130

Applicant : Gantier *et al.*
Patent No. : 7,611,700
Issue Date : November 3, 2009
Serial No. : 10/658,834
Filed : September 8, 2003

Attorney's Docket No.: 3800073.00005 / 922
Request for Correction to Issued Certificate of Correction

HAND-ANNOTATED CORRECTIONS TO THE
CERTIFICATE OF CORRECTION
ISSUED ON 22 MARCH 2010

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,611,700 B2
APPLICATION NO. : 10/658834
DATED : November 3, 2009
INVENTOR(S) : Gantier et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 7, lines 15-16, please replace "SEQ ID Nos: 233-289), 989-1015, and 1016-1302)compared" with -- SEQ ID Nos: 233-289, 989-1015, and 1016-1302) compared --;

At column 7, line 47, please replace "(SEQ ID NO:216)based" with -- (SEQ ID NO:216) based --;

At column 7, lines 51-52, please replace "SEQ ID Nos: 794-849), compared" with -- SEQ ID Nos: 794-849) compared --;

At column 7, lines 57-58, please replace "SEQ ID Nos: 896-939), compared" with -- SEQ ID Nos: 896-939) compared --;

At column 7, line 64, please replace "(SEQ ID NO:211),based" with -- (SEQ ID NO:211), based --;

At column 8, line 2, please replace "SEQ ID Nos: 729-760), compared" with -- SEQ ID Nos: 729-760) compared --;

At column 8, lines 8-9, please replace "SEQ ID Nos: 761-763), compared" with -- SEQ ID Nos: 761-763) compared --;

At column 8, lines 16-17, please replace "Nos: 940-977), compared to the wild-type sequence (SEQ ID NO: 201),based" with -- Nos: 940-977) compared to the wild-type sequence (SEQ ID NO: 201), based --;

At column 8, lines 21-22, please replace "SEQ ID Nos: 401-428), compared to residues 1-1000" with --SEQ ID Nos: 401-428) compared to residues 1-100 --;

At column 8, lines 29-30, please replace "SEQ ID Nos: 362-400), compared to the wild-type sequence (SEQ ID NO: 202),based" with -- SEQ ID Nos: 362-400) compared to the wild-type sequence (SEQ ID NO: 202), based --;

At column 8, lines 35-36, please replace "SEQ ID Nos: 603-630), compared" with -- SEQ ID Nos: 603-630) compared --;


At column 8, lines 40-41, please replace "SEQ ID Nos: 429-476), compared" with -- SEQ ID Nos: 429-476) compared --;

At column 8, lines 46-47, please replace "SEQ ID Nos:477-498), compared" with -- SEQ ID Nos: 477-498) compared --;

At column 8, lines 52-53, please replace "SEQ ID Nos: 543-567), compared" with -- SEQ ID Nos: 543-567) compared --;

Signed and Sealed this

Fourth Day of May, 2010



David J. Kappos
Director of the United States Patent and Trademark Office

At column 8, lines 58-59, please replace "SEQ ID Nos: 568-602), compared" with -- SEQ ID Nos: 568-602) compared --;

At column 8, lines 64-65, please replace "SEQ ID Nos: 499-542), compared" with -- SEQ ID Nos: 499-542) compared --;

At column 47, line 50, please replace "IFN α cytokines" with -- IFN α cytokines --;

At column 47, line 57, please replace "herein The" with -- herein. The --;

At column 52, line 41, please replace "10/658,355,filed" with -- 10/658,355, filed --;

At column 66, line 50, please replace "prostatate" with -- prostate --;

At column 74, line 29, please replace "aliquots" with -- aliquots --;

At column 74, line 33, please replace "analysis.Residual" with -- analysis. Residual --;

At column 74, line 26, please replace "IFN α " with -- IFN- α --.

Column 87, line 32 to Column 87, line 47 should read

1. An isolated interferon (IFN) alpha cytokine, comprising an amino acid replacement in its sequence of amino acids, wherein:

an amino acid replacement is E41Q, whereby the interferon alpha cytokine exhibits increased resistance to proteolysis so that it can be administered orally compared to the unmodified interferon alpha cytokine that does not comprise the amino acid replacement; and
in the interferon-alpha cytokine the interferon is not glycosylated at E41Q; and
the unmodified interferon alpha cytokine is selected from among an interferon α -2b (IFN α -2b), an interferon α -2a (IFN α -2a), an interferon ~~α -2c~~^{8-2c} (IFN α -2c) and consensus interferon whose sequences are set forth in SEQ ID Nos. 1, 182, 185 and 232, respectively.

Column 87, line 48 to Column 87, line 64 should read

2. An interferon alpha cytokine selected from among IFN α -2b, IFN α -2a, IFN α -2c, consensus interferon, IFN α -c, IFN α -d, IFN α -5, IFN α -6, IFN α -4, IFN α -4b, IFN α -I, IFN α -J, IFN α -H, IFN α -F and IFN α -8, each comprising the modification E41Q, wherein:

the sequence of a human wild-type interferon alpha for each of IFN α -2b, IFN α -2a, IFN α -2c, consensus interferon, IFN α -c, IFN α -d, IFN α -5, IFN α -6, IFN α -4, IFN α -4b, IFN α -I, IFN α -J, IFN α -H, IFN α -F and IFN α -8; is set forth in SEQ ID Nos. 1, 182, 185, 232, 183 and 186-195, respectively; the modification at E41Q increases resistance of the interferon alpha cytokine so that it can be administered orally;

the interferon alpha cytokine is not glycosylated at E41Q; and

residue 1 in each SEQ ID corresponds to residue 1 of the mature interferon-alpha.